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ABSTRACT
Tara Rutter
262
Methylphenidate (MPH) is a common stimulant medication that has demonstrated
efficacy in treatment among individuals with attention deficit hyperactivity disorder
(ADHD) as well as those with co-occurring oppositional defiant disorder (ODD)
symptoms (Connor et al., 2002, Cortese et al., 2018). However, there are currently no
known reliable markers to predict response to MPH (Kim et al., 2015) and current
approaches rely on trial-and-error by patients. Electroencephalographic (EEG) methods
show promise as one tool to identify and predict MPH response. The current study
examined relations between EEG frequencies and perceived response to MPH across
both ADHD and ODD symptoms utilizing caregiver report on the Strengths and
Weaknesses of Attention-Deficit/Hyperactivity Symptoms and Normal Behaviors
(SWAN; Swanson et al., 2012). Participants included 30 children with ADHD (70%
male) between the ages of 7 -11 years (MAge = 121.27 months, SD = 16.47 months) and
their primary caregivers. Children’s absolute power frequencies were gathered during a
resting state EEG paradigm. Caregivers completed measures regarding their child’s
medication history, and retrospectively rated their child’s ADHD and ODD symptoms
across pre-MPH and optimal MPH dosage timepoints. Results indicated that alpha
frequency was marginally predictive of SWAN scores at optimal-MPH dosage while
controlling for SWAN scores prior to MPH (p = .058). No other frequency bands
examined demonstrated significant relations. Given the small sample size and low
statistical power of this study, the results may underestimate relations between EEG

frequencies and SWAN scores. These findings provide preliminary support for EEG
spectral power as a potential predictor of MPH response, lending credence for future
investigation and potential clinical utility.
Keywords: ADHD; stimulant response; biomarkers; electroencephalography

CHAPTER I - INTRODUCTION
Attention Deficit Hyperactivity Disorder (ADHD) is a common psychiatric
disorder evident in the early developmental period and characterized by symptoms of
inattention, hyperactivity-impulsivity, or both across a variety of settings (American
Psychiatric Association [APA], 2013). ADHD symptoms are associated with poorer
academic, social, and occupational outcomes compared to those with typical development
(Fredriksen et al., 2014; Owens & Jackson, 2017; Sciberras et al., 2009). Current
estimates indicate a worldwide prevalence rate of 5.3 percent (Polanczyk et al., 2014),
with diagnostic rates in the United States rising over the past 20 years (Xu et al., 2018). It
is estimated up to 60% of individuals diagnosed with ADHD present with comorbid
oppositional defiant disorder (ODD; Burke et al., 2002; Noordermeer et al., 2017),
suggesting etiological overlap.
Despite the heterogeneity of this disorder, effective treatments for ADHD
symptoms exist. The most validated of these are: (1) psychopharmacological treatments
and (2) behavioral interventions, with the two modalities often used in conjunction to
target impairment (MTA Cooperative Group, 2004). The extant literature on
psychostimulant medications to address impairing ADHD symptoms is abundant,
surpassing any other body of literature addressing childhood psychiatric disorder
treatment (Greenhill et al.,1999; Greenhill et al., 2002). Both methylphenidate (MPH)
and mixed amphetamine salts are within the psychostimulant medication class, each
uniquely targeting synaptic dopamine availability (Volkow et al., 2002). MPH is the most
common stimulant used for individuals with ADHD and is effective for approximately
65-70% of children for whom it is prescribed (Cortese et al., 2018).

While most individuals with ADHD demonstrate significant symptom
improvement utilizing MPH, a substantial percentage (approximately 30%) report little
alleviation across impairing ADHD symptoms and thus are considered “non-responders”
(Hodgkins et al., 2012). Other available stimulant medications such as amphetamine salts
or non-stimulant medications are generally trialed when individuals are considered MPH
non-responders. Less is known about individual differential response to medications, as
investigations comparing medication effects across stimulants are sparse (Faraone &
Buitelaar, 2010). Even less is known about response to MPH when individuals with
ADHD present with concurrent ODD symptoms. Within the framework of precision
medicine, much is left to be explored in predicting which medication may work best—
and for whom—among individuals diagnosed with ADHD.
Electroencephalography (EEG) has shown promise as a viable clinical tool to
understand the heterogeneity of ADHD through neurophysiological markers. Recently,
EEG methods have been employed to identify biomarkers of ADHD diagnosis and
medication response (Lenartowicz & Loo, 2014). EEG is a non-invasive technique to
study brain dynamics at the millisecond-level (Puce & Hämäläinen, 2017). EEG data are
wide-ranging; information that can be extracted includes: (1) the absolute magnitude of
oscillations (e.g., quantifying the spectral power signal), which broadly measures brain
state; (2) event-related potentials (ERPs); and (3) scalp topography, measuring numerous
electrical contributions across electrodes (Lenartowicz & Loo, 2014). Investigations of
frequency bands (e.g., alpha, beta, theta, delta) are calculated through EEG; the term
frequency signifies the number of oscillations or cycles within a time period, generally
calculated as oscillations per second (Hz). In existing literature, the common ranges for

each frequency band are as follows: The alpha band is denoted by 8-12 Hz range, the beta
band is denoted by a range of 13 – 30 Hz. The theta band is denoted by 4-7 Hz range, and
the delta band is denoted by a range of 4 Hz or less.
Literature examining relations between neurophysiology, ADHD symptoms, and
medication response has emerged within the past 20 years, with much yet to be explored.
EEG investigations demonstrate consistent findings of increased frontal and central theta
among individuals with ADHD, however, there are considerably mixed findings across
other bands (Loo & Barkley, 2005). The effects of MPH among ADHD individuals have
been demonstrated to improve abnormal EEG activity, with consistent findings that MPH
decreases theta activity (Clarke et al., 2002). However, findings across other bands
appears quite mixed, likely due to varied methods and age ranges examined (for a review,
see Loo & Barkley, 2005). MPH appears to be effective for patients with ADHD and
coexisting ODD (Connor, 2015; Kolko et al., 1999). Yet, little is known about which
biological markers may predict MPH response in this population. Examining the role of
EEG spectral power on children’s clinical presentations—both off MPH and at optimal
MPH dosage—would substantially build upon the existing literature.
The study’s overall goal is to determine potential biomarker associations of MPH
response (via neurophysiological data) and retrospective parent reported changes in
ADHD and ODD symptoms (both pre-MPH and at optimal dosage). This investigation is
unique in examining concurrent dimensional symptoms of ODD, the most common
coexisting psychiatric disorder within this population. I aim to investigate whether EEG
spectral power demonstrates relations to improvements in ADHD and ODD symptoms at
optimal MPH dosage among children in middle childhood.

In the following sections, I outline the theoretical reasoning for this investigation.
First, I provide an overview of ADHD. I then outline ODD symptoms among ADHD
populations. Following this, I provide an overview of EEG as a potential clinical tool to
understanding fundamental neurophysiology among ADHD populations and provide
current findings as it pertains to this study. Next, I discuss empirical investigations of
MPH as a treatment for ADHD symptoms. Finally, I provide evidence for investigating
EEG spectral power as a potential marker for MPH response.
Attention Deficit Hyperactivity Disorder
ADHD is a neurodevelopmental disorder characterized by at least 6 of 9 outlined
impairing symptoms of inattention and/or hyperactivity-impulsivity domains across
multiple settings (APA, 2013). Nearly 70% of individuals diagnosed with ADHD in
childhood continue to demonstrate impairing symptoms in adulthood (Sibley et al.,
2022), underscoring the importance of identifying effective treatments. Symptom profiles
and severity can vary across the lifespan; inattention domain symptoms often persist
within adulthood while hyperactive-impulsive symptoms are often present in early
childhood and attenuate to subthreshold clinical levels in adulthood (Lahey et al., 2005).
However, the subject of hyperactive-impulsive symptom remission is debated (for a
review, see Polanczyk & Rohde, 2007).
Additionally, the presence of coexisting psychiatric diagnoses across
internalizing and externalizing disorders is well-documented within this population.
Genomic studies suggest a partial etiological overlap for coexisting externalizing
symptoms including ODD (Brikell et al., 2018; Hamshere et al., 2013). Recent literature
indicates that 6 in 10 children with ADHD have at least one concurrent psychiatric

diagnosis, which may contribute to further and more severe impairment in functioning
(Danielson et al., 2018). Broadly, coexisting disorders among ADHD populations are
associated with a myriad of health impairments, including increased hospitalization rates
and suicidality (Biederman et al., 2008a).
Heterogeneity of ADHD
ADHD is a considerably heterogenous disorder that can vary in symptom severity
across the lifespan. Generally, hyperactive-impulsive symptoms attenuate across
adolescence and into adulthood (Molina et al., 2009); however, this remittance does not
appear to influence global symptom severity across inattentive and coexisting ODD
symptoms (Sibley et al., 2012). This heterogeneity has provided difficulties in
categorization attempts within the Diagnostic and Statistical Manuel of Mental
Disorders, Fifth Edition (DSM-5; APA, 2013). Currently, the DSM-5 lists three subtypes
of the disorder in order to capture an individual’s unique behavioral presentation:
Predominantly Inattentive Subtype, Predominantly Hyperactive-Impulsive Subtype, and
Combined Presentation (APA, 2013). However, studies examining diagnostic
classification have demonstrated challenges validating these subtypes through biological
markers, and inconsistencies in identifying differences across subtypes (Rowland et al.,
2008). These classifications also do not predict the course of impairing symptoms across
development (Loo et al., 2018). Overall, the current delineation of subtypes within the
DSM-5 do not appear to have particular clinical utility, nor do these subtypes outlined
predict treatment response. A biologically based approach may prove more useful to
understanding this neurodevelopmental disorder and psychiatric medication response.
Epidemiology

To date, 9.4 percent children in the United States have received a diagnosis of
ADHD within their lifetime; 8.4% of U.S. children have a current diagnosis of ADHD
(Danielson et al., 2018). A recent investigation by the National Survey of Children’s
Health found that 63.8 percent of children with a diagnosis of ADHD have at least one
coexisting psychiatric condition (Danielson et al., 2018). While the DSM-5 previously
estimated ADHD prevalence to be between 3 and 5 percent (APA, 2013), a weighted
prevalence estimate of diagnosed ADHD from 2015 to 2016 was 10.2 percent (Xu et al.,
2018). Importantly, the extant literature provides a clear consensus that ADHD is not
overdiagnosed within the United States, contrary to popular belief (Sciutto & Eisenberg,
2007). Numerous factors are implicated in the diagnostic prevalence increase, including
increased awareness of the disorder, increased health care accessibility through the
Affordable Care Act, changes to diagnostic criteria within the DSM to reflect a subtype
of predominantly inattentive symptoms, decreased stigma, and increased consensus
surrounding recommendation for early identification among professionals (Xu et al.,
2018).
Investigations of sex differences consistently demonstrate the disorder is more
prevalent among males, with a 3:1 male-to-female ratio in community-based samples
(Willcutt, 2012). Theories of this higher prevalence rate vary. from age-related
explanations of attenuation of hyperactive-impulsive symptoms, to delayed diagnostic
identification among females with ADHD, to a later onset of symptoms among females
(Agnew-Blais et al., 2016; Murray et al., 2019; Williamson & Johnston, 2015). Notably,
meta-analysis indicates that during the school years, females are less likely to be referred
for ADHD assessment due to confounding psychiatric symptoms that receive greater or

more immediate attention, such as depression or anxiety (Gershon & Gershon, 2002).
Further, males are more likely to demonstrate impairing externalizing and/or disruptive
behavior during school years and are more likely to be referred for diagnostic assessment
(Martel, 2013). Recent theories of the male-to-female ratio include both the mean
difference model, in which the mean symptom severity for males is closer to clinical
diagnostic threshold, as well as the variance difference model, in which males
demonstrate more extreme severities of symptom presentation across the distribution
(Arnett et al., 2015). Results from an investigation by Arnett and colleagues (2015)
indicate that the 3:1 male-to-female ratio appears to be valid and not the result of measure
invariance (Arnett et al., 2015).
Etiology
The etiological mechanisms of ADHD are multifactorial. Currently, the etiology
of this disorder can be conceptualized as a constellation of genetic, neurobiological, and
environmental risk factors. The heritability for ADHD has been previously shown via
twin studies, varying between 77 to 88% (Faraone & Larsson, 2019). Numerous studies
investigating twin zygosity and ADHD also lend credence to a genetic etiology, with
previous estimates of monozygotic concordance rates at nearly 80% (for an overview, see
Biederman, 2005). Methods to examine genetic etiology can employ several approaches,
such as genome scans with no a priori hypotheses, and theoretically driven candidate
gene investigations. A genomewide linkage analysis of 204 families (853 individuals and
270 affected sibling pairs) suggests particular chromosomal locations (namely, 16p13 and
17p11) are regions “likely to harbor risk genes for ADHD” (Ogdie et al., 2003). Further,
meta-analyses of ADHD candidate genes implicate DRD4, the D4 dopamine receptor

gene (Gizer et al., 2009). In particular, common polymorphisms among individuals with
ADHD include the dopamine receptor D4 4-repeat allele (DRD4*4), the 2-repeat allele
(DRD4*2), and the 7-repeat allele (DRD4*7), with prevalence rates at 65.1%, 8.8%, and
19.2%, respectively (Chang et al., 1996). DRD4*7, the 7-repeat allele of dopamine
receptor D4, has been of particular interest among ADHD etiological investigations,
given the high prevalence of the polymorphism and increased odds ratios of hyperactivity
and inattention scores (Tovo-Rodrigues et al., 2013). Interestingly, this polymorphism
appears to be region-specific (Hawi et al.,2000). However, results from genetic
investigations have yielded inconsistent findings, with theories that the genotype must
interact with a particular environmental risk to yield impairing symptoms (Kieling et al.,
2008).
Environmental Risk Factors
While genetic and biological factors are strongly implicated in etiology,
additional influences conferring risk for ADHD include several perinatal factors such as
maternal infection and maternal immune activation (Strickland, 2014) and perinatal
exposure to nicotine or alcohol (Milberger et al., 1998). Other environmental factors
demonstrated to increase risk for ADHD symptoms include exposure to polychlorinated
biphenyl compounds, pregnancy or delivery complications, poor maternal health,
maternal age, labor duration, low birth weight, eclampsia, or hemorrhage (Banerjee et al.,
2007). While there are clear indications for a genetic basis, the etiology of ADHD strikes
similarities to the etiology of autism spectrum disorder; for both neurodevelopmental
disorders, no single risk factor has been identified as the sole causal mechanism (Kieling

et al., 2008). Thus, while existing literature points heavily to genetic contributions, the
consensus is that the disorder is likely due to gene-environment interactions.
Comorbid Oppositional Defiant Disorder
Coexisting psychiatric disorders are the rule, rather than the exception, among
ADHD populations, and are considered a “key clinical feature of ADHD” (Biederman,
2005). ODD is the most common coexisting psychiatric disorder among individuals with
ADHD, with prevalence rates upwards of 50% (Nock et al., 2007). The DSM-5 outlines
ODD symptoms as “a pattern of angry and irritable mood, argumentative and defiant
behavior, or vindictiveness, demonstrated at least once per week over a period of six
months for children 5 years and older” (APA, 2013, p. 462). Severity (mild, moderate, or
severe) is dependent on the number of settings in which symptoms occur (APA, 2013).
Both ADHD and ODD symptoms frequently manifest during the preschool years
(Lavigne et al., 2009; Riddle et al., 2013), and demonstrate adverse developmental
outcomes (Forehand et al., 2016). To date, only a few studies have examined
bidirectional relations between symptoms of ADHD and ODD across youth populations.
Overall, the existing literature suggests ADHD symptoms predict later ODD symptoms,
but ODD symptoms do not prospectively predict later symptoms of ADHD among
school-age children (Burke et al., 2005; Burns & Walsh, 2002). Literature investigating
these relations in preschool-aged children demonstrated mixed findings: ADHD
symptoms predicted later ODD and CD symptoms in some investigations (Lahey et al.,
2009; Wåhlstedt et al., 2008). However, these conclusions are limited, given reduced
effect sizes when early conduct problems are controlled for in analyses. More recently, a
longitudinal investigation of preschoolers suggests ADHD symptoms predict later

argumentative and defiant symptoms (Harvey et al., 2016). Overall, the relations between
these diagnostic symptoms are yet to be well-understood.
Etiology
The shared etiology between ODD and ADHD is currently unknown, but
literature demonstrates some heritability (Faraone et al., 1998). Common genetic risk
factors appear to explain covariation of ADHD and ODD (Dick et al., 2005; Nadder et
al., 2002). It is important to note, however, that genetic studies indicate the development
of ODD symptoms is less likely to be genetically influenced than the development of
ADHD symptoms alone, marking the importance of understanding ODD symptoms from
a gene-by-environment interaction (Burt et al., 2001). A recent investigation found that
family histories of ADHD and ODD/CD symptoms uniquely predict ADHD and
coexisting anger/irritable symptoms in children (Harvey et al., 2016). Tuvblad and
colleagues (2009) found that covariation of ADHD, ODD, and CD symptoms among 9to-10-year-old children were explained by a latent externalizing behavior factor; with
57% of the total variance in the latent factor explained by a common genetic risk factor
(Tuvblad et al., 2009). The authors assert their findings suggest that a common genetic
influence marks liability for the co-occurrence of ADHD, ODD and CD symptoms
among those in middle childhood.
Animal models of gene-environment interactions of ADHD and coexisting
psychiatric symptoms suggest an interaction between tobacco exposure during the
perinatal period with the DAT1 dopamine transporter gene, providing the catalyst to upregulate nicotine receptors (for a review, see Russell, 2011). Kahn and colleagues (2003)
prospectively investigated children ages 6 months to 60 months to examine both

independent and joint contributions of DAT1 polymorphisms and maternal prenatal
smoking on ADHD and ODD symptoms (Kahn et al., 2003). The authors found that
independent contributions of DAT1 and prenatal maternal smoke exposure did not
significantly account for increased ODD symptoms; however, children who were
homozygous for the DAT1 10-repeat allele and also exposed to prenatal smoking
demonstrated increased risk of hyperactive-impulsive and ODD symptoms (Kahn et al.,
2003). Given biological factors implicated in ADHD etiology and partial heritability of
ODD, examining the link between biological indices and treatment outcomes in this
population is crucial. The following section will describe the use of EEG to denote
neurophysiological differences within ADHD populations and review the extant
literature.
Electroencephalography
EEG is a neurophysiological method that allows for the temporal evaluation of
electrical activity stemming from the brain and can determine relative electrical activity
across brain regions (Davidson et al., 2000). EEG recordings have been employed to
study human behavior since Hans Berger used radio equipment to examine brain
electrical activity in the early 1920’s (Britton et al., 2016). The concept of brain waves
was verified through Adrian and Matthews’ (1934) investigation, in which the authors
identified alpha rhythms—that is, oscillations between 10 to 12 Hz (Adrian & Matthews,
1934). EEG is both non-invasive and cost-effective (Bailey, 2014). It is most commonly
used as a tool to assess seizure activity and diagnose epilepsy; however, clinical and
research purposes for EEG vary widely and include sleep disorder physiology, biological

indices of neurodevelopmental disorders, and assessment of medication effects (Davidson
et al., 2000)
Broadly, brain electrophysiology can be examined in three ways: 1) event related
potentials, in which the average of EEG signals is time- and phase-locked to a stimulus or
subject response; 2) continuous EEG, in which the absolute or relative magnitude of
oscillations is calculated; and 3) scalp topography, providing a visualization of the brain
regions implicated in both continuous EEG and ERP (Britton et al., 2016). EEG
waveforms are measured and generated via differential amplification, in which one active
exploring electrode site is compared with another neighboring or distant reference
electrode, thus measuring electrical potential (Britton et al., 2016).
Neurodevelopmental research employing EEG methodology often aims to clarify
underlying mechanisms and biological markers of neurodevelopmental disorders (LauZhu et al., 2009). Among investigations of individuals diagnosed with ADHD, relations
have been found between frontal cortical abnormalities and ADHD symptoms (Barry et
al., 2003; Cortese, 2012; Monastra, 2008), as well as differences in ERP waveforms
(Kaiser et al., 2020), however, results of spectral topography investigations have been
highly variable (Thome et al., 2012). Overall, biological indices of ADHD remain
elusive with no clear consensus. The use of EEG may provide further clarification to the
etiology.
EEG Power Investigations in ADHD Populations
EEG has been employed as a tool to examine ADHD since Jasper and colleagues’
(1938) seminal investigation (Lenartowicz & Loo, 2014). Investigations of EEG
differences among children and adolescents with ADHD consistently demonstrate

increased theta activity among these populations (Clarke et al., 2003; Clarke et al., 2008).
This increased theta activity is posited to be reflective of cortical hypoarousal (Loo &
Barkley, 2004). The most consistent finding across investigations suggests that both
children and adults diagnosed with ADHD demonstrate increased absolute and relative
theta, decreased absolute and relative beta, and decreased absolute alpha compared to
their typically developing peers (Kirkland & Holton, 2019, Lenartowicz & Loo, 2014).
Significant group differences have also been found among adolescent populations as well
as adult populations, such that beta activity was significantly reduced compared to
typically-developing controls (Hermens et al., 2005; Lenartowicz & Loo, 2014), which is
posited to be reflective of reduced concentration or active thinking (Baumeister et al.,
2008). However, some studies suggest no differences in global or relative spectral power
(Skirrow et al., 2015; Clarke et al., 2002; Clarke et al., 2003). It is important to note that
EEG differences in alpha frequency (associated with an idle, relaxed state and associated
with creativity) demonstrate inconsistent findings between ADHD and typically
developing controls; relative power is often decreased among individuals with ADHD
(Clarke et al., 2002; Clarke et al., 2003; Clarke et al., 2008), although other investigations
found no significant differences among groups (Huang et al., 2018).
Prior to 2010, numerous investigations examined a potential “theta-to-beta ratio”
to differentiate ADHD diagnosis, with initial results demonstrating large (range = 0.62 3.08) effect sizes (Snyder & Hall, 2006). However, recent evidence examining the thetato-beta ratio points to replication errors across age ranges; overall findings indicate no
significant group differences between ADHD versus typically developing peers (Arns et
al., 2013; Saad et al., 2018). Finally, a meta-analysis by Arns and colleagues (2013)

reported decreased effect sizes in the theta-to-beta ratio comparing patients with ADHD
and typically-developing controls. Interestingly, the decreased effect sizes across years
was found to be driven by an increase in the theta-to-beta ratio among typically
developing groups, and not due to a decreased ratio among the ADHD groups (Arns et
al., 2013). Barring theta activity, the literature appears mixed given brain regions and age
ranges investigated.
Stimulant Medications
Stimulant medications are considered the first line of treatment for ADHD; of
these, MPH formulations are generally the first line of stimulant medications employed
(Briars & Todd, 2016). MPH alters dopaminergic neural transmission, increasing
dopamine and norepinephrine in the synaptic cleft (Capp et al., 2005). MPH is an FDAapproved medication to treat symptoms of ADHD, with well-documented efficacy
(Schachter et al., 2001). Several older studies raise the question of whether childhood
stimulant treatment demonstrates causal relations to later substance use disorder (Kollins
et al., 2001); however, numerous studies have debunked this theory (Barkley et al., 2003;
Biederman et al., 2008b; Loney et al., 2002).
EEG Relations of MPH Response in Children with ADHD
MPH has been demonstrated to improve abnormal EEG activity among
individuals with ADHD, with the most common finding demonstrating that MPH
attenuates absolute theta activity and increases absolute beta activity (Clarke et al., 2002).
However, the literature is inconsistent, and results across frequency bands demonstrate
mixed findings (Loo & Barkley, 2005).

Kirkland and Holton (2019) provide an excellent overview of the extant literature
investigating stimulant treatment effects, although not particular to MPH. Previous
investigations suggest that MPH use among children results in increased alpha activity in
both central and parietal regions during baseline conditions (Loo et al., 2004; Loo et al.,
2018). The authors found that among those who exhibited medication response, there was
an associated increased frontal beta activity; whereas non-responders demonstrated
decreased frontal beta activity (Loo et al., 2004). Further, increased frontal beta activity
following medication administration appears to be associated with medication-related
improvement in parent behavior ratings across both inattentive and hyperactive-impulsive
symptoms (Loo et al., 2004). Decreased right frontal theta activity also demonstrates
relations with improvements in parent-rated IA (Loo et al., 2004).
Few investigations have examined baseline neurophysiological predictors of MPH
response, which would provide outstanding clinical utility for children and families in
identifying medication treatment course. Gokten and colleagues (2019) provides the most
similar methodological approach to the current study: The authors examined the
relationship between initial EEG absolute power frequency bands (prior to the initiation
of methylphenidate treatment) and difference scores, as measured by the Conner’s Parent
Rating Scale short form, following 13 months of MPH treatment among children with
ADHD. The authors found that absolute frontal delta, frontal and central theta negatively
correlated with parent-reported Conner’s hyperactivity difference scores, that is,
elevations were related to symptom improvement. Additionally, the authors found that
absolute frontal beta and parietal beta positively correlated to parent-reported Conner’s
hyperactivity difference scores, that is, decreased beta power was related to more

improvement. Overall, among the stimulant class, decreased absolute theta and increased
absolute beta has been demonstrated to be associated to treatment response, whereas
treatment effects relations to alpha are mixed.
ODD symptoms have been examined through EEG methods in MPH response
investigations among individuals with ADHD. However, these symptoms are often
examined through broadband and categorical measures, such as the Child Behavior
Checklist (CBCL; Achenbach & Rescorla, 2001). While the CBCL is often employed to
determine standard scores across a variety if behaviors and accordingly maps items to
DSM-5 symptom domains, items reported are not exhaustive to the diagnostic criteria,
and do not capture a continuum of symptom presentation and severity and are prone to
social-cultural bias (Brites et al., 2015). Categorical scales utilized by measures such as
the CBCL or Conner’s Parent Rating Scales provide items reflective to the extent which a
specific psychopathology is present, which has the potential to exclude subtler variations
of symptom presentation. For example, item 10 on the CBCL reads, “Can’t sit still,
restless, or hyperactive” that is rated on the extent to which this behavior is present on a
0-2 scale and does not reflect the extent to which a child has relatively strong behavioral
control. Evaluation of disruptive or socially unacceptable behavior can vary across
cultures (Brites et al., 2015), thus, a dimensional approach to examining these symptoms
is warranted. The Strengths and Weaknesses of Attention-Deficit/Hyperactivity
Symptoms and Normal-behaviors (SWAN; Swanson et al., 2012) provides a culturallyresponsive approach, to better reflect symptom variability at the adaptive ends of
attention and activity regulation as well as at the symptomatic levels of these dimensions.
For example, the SWAN asks caregivers to rate how well their child “listens when

spoken to” (rating attentional skills) or “awaits turn” (rating activity regulation).
Dimensional discrimination from the SWAN is ascertained from the average (level zero),
such that extremes are represented both at the high (−1, −2, −3), and low (+1, +2, +3) end
of the spectrum (Brites et al., 2013).
Given that ODD symptoms often manifest in the preschool years and are
associated with poor developmental outcomes among individuals with ADHD, it is
surprising that neurophysiological relations of ODD symptoms have not been robustly
examined on and off-stimulants from a dimensional perspective. While differential
behavioral profiles have been previously demonstrated among children across EEG
frequencies, I am unaware of any research to date that has examined EEG predictors of
MPH response utilizing the SWAN. An examination of EEG predictors of MPH response
utilizing the SWAN provides the unique research opportunity to discern the degree to
which a child’s adaptive behavioral presentation (e.g., strengths in sustained attention,
attention to detail, behavioral inhibition) may be enhanced or degraded following MPH.
That is, use of the SWAN provides valuable information regarding the utility of MPH
among those with maladaptive behavioral profiles and those presenting with adaptive
strengths at baseline.
Current Study and Hypotheses
I will investigate the relations between EEG absolute frequencies and caregiverreported changes in ADHD and ODD symptoms among school-age young children with
ADHD. Overall, the goal of this study is to examine potential biomarkers linked to
caregiver perceptions of MPH response among young children with ADHD. This study
extends upon previous MPH response literature by examining dimensional symptoms and

is unique in its examination of continuum ODD symptoms in addition to ADHD
symptoms. The methodological approach aligns with NIMH RDoC criteria, such that
biologically-based groups are provided a dimensional phenotype. The results of this study
may illuminate the clinical utility of EEG to predict perceived MPH response among
school-age children with ADHD. Based on previous literature, the following hypotheses
were made:
Hypothesis 1: Baseline absolute alpha frequency will be significantly predictive
of change in caregiver-reported ADHD and ODD symptoms from pre-MPH to optimal
MPH dosage. Specifically, it was hypothesized that reduced alpha frequency would
predict greater symptom improvement (i.e., a significant negative relation between
variables of interest). While literature regarding alpha frequency and MPH response is
mixed, several investigations of baseline EEG profiles suggest that children with ADHD
demonstrate decreased absolute alpha frequency compared to typically-developing peers
(Kirkland & Holton, 2019, Lenartowicz & Loo, 2014).
Hypothesis 2: Baseline absolute beta1 frequency will be significantly predictive
of change in caregiver-reported ADHD and ODD symptoms from pre-MPH to optimal
MPH dosage. Specifically, it was hypothesized that decreased beta1 frequency would
predict greater symptom improvement (i.e., a significant negative relation between
variables of interest). One previous investigation found significant negative relations
between absolute beta frequency within the parietal and frontal regions and improvement
in Conner’s hyperactivity difference scores (Gokten et al., 2019).
Hypothesis 3: Baseline absolute beta2 frequency will be significantly predictive
of change in caregiver-reported ADHD and ODD symptoms from pre-MPH to optimal

MPH dosage. Specifically, it was hypothesized that decreased beta2 frequency would
predict greater symptom improvement (i.e., a significant negative relation between
variables of interest) based similarly on the beta1 frequency band findings by Gokten and
colleagues (2019) described above.
Hypothesis 4: Baseline absolute theta frequency will be significantly predictive of
change in caregiver-reported ADHD and ODD symptoms from pre-MPH to optimal
MPH dosage. Specifically, it was hypothesized that elevated theta frequency would
predict greater symptom improvement (i.e., a significant positive relation between
variables of interest). This hypothesis is based on substantial literature suggesting
individuals with ADHD demonstrate elevated baseline absolute and relative theta,
further, elevated frontal and central theta have demonstrated relations to symptom
improvement (Kirkland & Holton, 2019, Lenartowicz & Loo, 2014).
This study employs a cross-sectional, residualized change model. My independent
variables across separate hypotheses are the following: average alpha, beta1, beta2, and
theta frequencies. Given that I am examining residualized change scores derived from the
SWAN as a dependent variable, retrospective parent reported pre-MPH SWAN ratings
will serve an independent variable.
The residualized change models can be expressed as the following equation:
RSn2=β0+β1RSn1+β2Cn+en2.
The subscript n is representative of each participant, and subscripts 1 and 2 represent
timepoints. RSn2 represents participant’s SWAN score at optimal MPH (i.e., timepoint 2),
RSn1 represents participant’s SWAN score pre-MPH (i.e., at timepoint 1), and Cn
represents spectral power at the requency band (i.e., alpha. beta1, beta2, or theta). It is

important to note that both ANCOVA and multiple regression models are represented by
this equation. Castro-Schilo and Grimm (2018) describe that the measurement scale of Cn
(either grouping or continuous) determines if the data should be examined through
ANCOVA or a multiple regression model, respectively. Following recommendations
from Castro-Schilo and Grimm (2018) for analyzing two-occasion (e.g., repeated
measures) data, and given that each Cn across my four hypotheses represents a continuous
variable, multiple linear regression analyses was employed for the purposes of this
investigation. Multiple linear regression models are used to estimate relationships
between two or more independent variables and one dependent variable.

CHAPTER II – METHOD
Participants
This investigation was conducted as a subset of larger investigation examining
neurophysiological correlates among school-age children with a clinical diagnosis of
ADHD. The larger investigation and this sub-investigation were approved by the
Institutional Review Board at the University of Washington (STUDY00004534).
Participants in the larger investigation included children with ADHD and typicallydeveloping controls as well as their primary caregivers. Exclusion criteria for the larger
study was the following: Diagnosis of autism spectrum disorder, known genetic
syndrome(s), intellectual disability or global developmental delay, IQ < 80, perinatal
trauma, gestational age less than 32 weeks, prenatal exposure to substances, history of
seizures, or colorblindness. Children were administered a brief measure assessing their
cognitive abilities (WASI-II; Weschler, 2011) to verify IQ inclusion criteria. Participants
within the ADHD group from the larger study were eligible to complete this subinvestigation if they had ever been treated with a methylphenidate medication, which was
assessed during recruitment via a one-item screener.
A total of 31 children and their parents participated in this investigation. One
participant (n =1) was later disqualified and removed from analyses due to identification
of right central temporal discharges that were suggestive of Rolandic epilepsy or epilepsy
with centro-temporal spikes, thus meeting exclusion criteria. The final sample of
participants included 30 children (70% male, 30% female) ages 7-11 years old (M =

121.27 months; SD= 16.47 months) and their caregivers. Sample characteristics are
further detailed below in Table 1 and Table 2.
Table 1
Sample Demographics
Frequency
Sex
Male
Female
Ethnicity
European American/White
Multiracial
European American, Hispanic
African-American
Currently Prescribed MPH
Yes
No
Primary Caregiver Education
High School or Equivalent
Some College
4-year college
Master’s Level
Doctorate (PhD/MD)

Percentage

21
9

70.0
30.0

21
6
3
1

70.0
20.0
6.7
3.3

14
16

46.7
43.3

2
1
11
10
6

6.7
3.3
36.7
33.3
20.0

Procedures
Families were recruited for the parent investigation from ADHD diagnostic
clinics, research centers, community settings, and relevant social media posts within the
greater Seattle area. Caregivers completed demographic, medical, and other behavioral
measures during the larger main visit, including information regarding their child’s
psychiatric symptoms and health history. Children completed a 1-hour EEG session that
included resting and task-based paradigms, and underwent neuropsychological testing
lasting approximately 2 hours. During neuropsychological testing, children were

administered a brief cognitive assessment via a 2-subtest FSIQ from the Wechsler
Abbreviated Scale of Intelligence, Second Edition (WASI-II; Weschler, 2011) to ensure
inclusion criteria were met. A licensed clinical psychologist then reviewed the available
data and confirmed diagnostic status as part of the larger investigation.
Primary caregivers of participants within the ADHD group who had consented to
recontact for future research through the larger study were then recruited via phone and
email within two years of their child’s participation for the purposes of the current
investigation. Caregivers were provided a list of methylphenidate brand names and
completed a one-item screener, “Has your child ever taken methylphenidate, even if it
was a brief medication trial?” to discern MPH medication history. Those who responded,
“Yes, my child is currently taking a methylphenidate medication” or “Yes, but not
currently” were invited to participate in the study. Caregivers consented to the use of
their child’s resting state data (acquired during the larger investigation), completion of a
one-time HIPAA-compliant online questionnaire containing 2 repeated measures
(SWAN, NICHQ Vanderbilt Performance subscales) and 1 measure of medication side
effects (NICHQ Vanderbilt Side Effects subscale), and a brief clinical phone interview to
provide specific examples pertaining to their survey responses. Caregivers were provided
a survey link to the online questionnaire and were instructed to retrospectively rate their
child’s ADHD and ODD symptoms prior to MPH treatment, and then were instructed to
rate their child’s ADHD and ODD symptoms at optimal MPH dosage. Among those who
did not achieve an optimal dosage or those who discontinued MPH prior to one month,
caregivers were instructed to rate their child’s ADHD and ODD symptoms at the highest

dose received for longer than three days. Caregivers then completed a brief phone
interview following completion of the questionnaire to further provide examples of their
child’s pre-MPH and optimal-MPH functioning and behaviors. Caregivers were offered a
$20 gift card in compensation for their participation for completing both the
questionnaire and the brief follow-up interview.
EEG Acquisition
Children underwent a one-hour EEG visit consisting of 5 paradigms as part of the
larger study. Participants were comfortably seated at 70cm from the presentation screen
throughout EEG collection. A high-density 128-channel EGI Phillips GSN Hydrocel net
and Netstation Acquisition software (version 4.5.6) with a 400-series high impedance
amplifier (Electric Geodesics Inc., EGI, Eugene, OR) was used to collect continuous
EEG data. At the start of the session, electrode impedances were reduced to below 50
kOhms to minimize signal-to-noise ratio. Additionally, examiners monitored and re-wet
electrodes with saline solution throughout the EEG session. The vertex electrode—analog
filtered (0.1 Hz high-pass, 100 Hz elliptical low-pass), amplified, and digitized with a
sampling rate of 1000 Hz—served as reference for EEG signals. Timing of the
presentation of the visual stimuli during the resting state, lights-on, eyes open tasks on the
subject monitor was recorded using a Cedrus Stimtracker (Cedrus Corporation, San
Pedro, CA).
Measures
Diagnostic Status

ADHD diagnosis of participants were confirmed as part of the larger investigation
by a licensed clinical psychologist through review of caregiver report on the CBCL 6-18
(Achenbach & Rescorla, 2001), caregiver report on the KSADS-COMP (Townsend et al.,
2019), clinical interview with the caregiver, an ADHD checklist, and/or behavioral
observations during the larger study visit. Diagnostic status informed eligibility criteria
for this sub-investigation.
Cognitive Abilities
Participants completed the WASI-II (Weschler, 2011) during the larger study
visit. The WASI is a brief assessment of cognitive abilities for individuals ages 6 years 0
months to 90 years 11 months. The larger study utilized the Vocabulary and Matrix
Reasoning subtests to derive a 2-subscale full scale IQ for each child. Each child’s FSIQ2 standard score was used to assess his or her cognitive abilities and included as a
potential covariate in the current study. An FSIQ score below 80 was exclusionary for the
parent study. The WASI-II was normed using 2,300 individuals aged 6 years 0 months to
90 years 11 months utilizing a representative sample of the United States population
based on age, sex, race, ethnicity, educational level, and region. The alpha coefficient of
the WASI-II FSIQ-2 composites was  = .94. The WASI-II was also tested against other
measures of intelligence (WASI, WISC-IV, WAIS-IV); correlations ranged from
acceptable (.71) to excellent (.92).
Demographic Variables
Primary caregivers completed a demographic questionnaire as part of the larger
study, detailing primary caregiver education level, child age, child sex, and ethnicity as

part of a Brief Medical History Questionnaire. Potential covariates were examined from
the demographic questionnaire and analyzed to determine if they should be controlled for
in subsequent analyses. Primary caregivers also completed brief survey items detailing if
their child was currently taking MPH, the MPH medication brand prescribed, and
approximate length of time the medication was taken.
EEG Spectral Analysis
A 5-minute, continuous resting state lights-on paradigm was selected for the
purposes of this investigation and in accordance with previous literature. Resting state
EEG provides a measure of overall brain activity in non-aroused or evoked states, noting
function in the absence of instructions and task demands (Bai et al., 2017). Other
paradigms from the larger study (e.g., easy event-related potential task, hard event-related
potential task, auditory oddball task) were thus not examined, as my investigation aims to
examine children’s passive fundamental brain state.
Raw EEG spectral power were processed through the larger study following
procedures similar to the Batch EEG Automated Processing Platform software (BEAPP;
Levin et al., 2018). BEAPP is MATLAB-based, free software program available through
GitHub, and has been employed to identify biomarkers of neurodevelopmental disorders,
including neurophysiological indices of autism spectrum disorder in infancy (GabardDurnam et al., 2019). EEG data was processed via Matlab R2018b using EEGLAB 15
and functions and extensions. Initial processing involved all resting state data, 112
channels remained following exclusion of 14 rim channels and eye electrodes. Data were
first downsampled to 250 Hz and bandpass filtered at 0.3-80 Hz. Next, the EEGLAB

Cleanline plugin was employed and removed electrical line noise from 55-65 Hz. Bad
channels were then automatically deleted and subsequently interpolated following
HAPPE preprocessing pipeline methods outlined by Gabard-Durnham and colleagues
(2018). Average referencing preceded channel interpolation. Extended independent
component analysis (ICA) was conducted, utilizing primary component analysis
dimension reduction in order to identify and remove artifact components following the
BEAPP pipeline methods (Levin et al., 2018). Welch’s method was utilized to perform
Fast Fourier Transformation (FFT) FFT is a mathematical method for transforming a
function of time into a function of frequency and is frequently employed in EEG analyses
(Nunez et al., 1997). Power values were log-transformed to facilitate direct comparisons
with other investigations and in order to run parametric analyses (Cohen, 2014). Spectral
power was calculated for 4 frequency bands: alpha (8-12 Hz), beta1 (13-20 hz), beta2
(21-30 Hz), and theta (4-7 Hz). Delta was not included as part of this analyses due to
significant artifact conflation (e.g., eye movements, tongue movements, talking, chewing,
movement artifacts). As a practical constraint, frequency bands (alpha, beta1, beta2,
theta) were separately averaged across anterior frontal, frontal, central, and parietal
regions of the scalp to serve as the primary variables of interest.
ADHD and ODD Symptoms
Parent-reported ADHD and ODD symptom severity pre-MPH and at the
optimal/highest dosage were assessed via the Strengths and Weakness in ADHD
Symptoms and Normal Behavior Scale (SWAN; Swanson et al., 2006). The SWAN
measures the 18 ADHD symptoms as outlined through the DSM-5, as well as comorbid

ODD symptoms across 8 items. The SWAN uses a balanced, 7-point Likert scale, with
anchors ranging from -3 = far below (relative to same-aged peers) to 3= far above
(relative to same-aged peers). Items marked “below” or “far below” indicate clinical
impairment. For ease of interpretation in this study, SWAN scores were reverse coded
such that greater scores indicated greater clinical impairment. The SWAN has
demonstrated high internal consistency (Cronbach’s alpha > .90; Lakes et al., 2013) and
strong external validity (Arnett et al., 2013). In this study, Cronbach’s alpha for pre-MPH
SWAN scores were .95 for the Inattention subscale, .94 for the Hyperactivity-Impulsivity
subscale, .92 for the ODD subscale, and .88 for total SWAN scores. Cronbach’s alpha for
optimal-MPJH SWAN scores were .95 for the Inattention subscale, .93 for the
Hyperactivity-Impulsivity subscale, .97 for the ODD subscale, and .95 for the total
SWAN scores at optimal MPH. A total score of averaged ratings across ODD and ADHD
symptoms were then computed from the SWAN for the purposes of this investigation.
Data Entry and Preparation
Data were entered into the Statistical Package for the Social Sciences (SPSS)
Version 27.0 software and were cross-checked for accuracy. Primary variables of interest
included averaged alpha, beta1, beta2, and theta frequencies (separate independent
variables), children’s ADHD and ODD symptoms prior to MPH (covariate; SWAN
Timepoint 1), and children’s ADHD and ODD symptoms at optimal MPH (dependent
variable; SWAN Timepoint 2). All variables were continuous data.
Power Analysis

An a priori power analysis was conducted using G*Power (Faul et al, 2007) to
determine adequate power and appropriate sample size for the current investigation. PreMPH SWAN scores served as a covariate in the model; no other covariates were
detected. Using standard parameters of power at .8 and alpha set at .05, results indicated
that a sample size of 68 was needed for a moderate Cohen’s F2 effect size of .15. The
current study analyses were thus underpowered. Practical constraints limiting study
recruitment are further outlined within the discussion section.
Preliminary Analyses
Preliminary data pre-screening evaluated assumptions of multiple regression and
reviewed the data for missingness and outliers. No missingness was detected. Outliers
were examined using histograms and box-and-whisker plots. No clear reasons for
exclusion were identified and thus these datapoints were retained to represent variability
within the clinical sample. No demographic variables (age, sex, ethnicity, primary
caregiver highest level of education) were significantly correlated with variables of
interest, nor were children’s abbreviated IQ scores, and thus these variables were not
controlled for in subsequent analyses. Prior to data analysis, the data were examined for
the following violations of the assumptions of multiple regression, as outlined below:
Linearity
This assumption states that the relation of the independent variable (IV) and the
dependent variable (DV) must be linear. Data were examined graphically using a scatterplot with a best fitting line to determine linearity, and to ensure the data do not follow

other trajectories (e.g., cubic, quadratic). Data appeared randomly and evenly dispersed,
thus the assumption was met.
Homoscedasticity
This assumption refers to the variance of the residuals being constant across all
values of the independent variables (Field, 2009). This assumption was tested via visual
inspection by plotting predicted values and residuals. To meet the assumption, data
should appear evenly dispersed, with no significant outliers. If a funneling pattern
emerges with the data, in which there are various levels of diffusion at different values of
the IV, it would represent heteroscedasticity, violating this assumption. Data appeared
evenly dispersed with no significant outliers.
Independence
The assumption of independence states that the errors of estimation are
statistically independent; meaning a residual from one observation is not related to the
residual of another observation. To test this, I conducted the Durbin-Watson test (Field,
2009). Values less than one or greater than three indicate residual dependence within the
sample (Cohen et al., 2003). Durbin-Watson values were found to be within the
appropriate range.
Normality
This assumption states there is normal distribution in the errors in estimation of the
outcome variable. Accordingly, residuals distribution should be in concordance with a
normal distribution (Field, 2009). To inspect this, I examined the data visually with a
histogram as well as a probability-probability plot (P-P plot). The histogram of the

residuals revealed a normal distribution, and the P-P plot shows the z-scores plotted
tightly along the diagonal line, which was sufficient evidence to conclude that the
residuals of the data are normally distributed (Field, 2009)
Multicollinearity
Multicollinearity occurs when there is high covariance between two predictor
variables (Field, 2009). I assessed multicollinearity through preliminary correlational
analyses. If two of my predictor variables are highly correlated with one another (r > .80),
I may consider combining the two predictors. Other tests of multicollinearity may include
the VIF (value greater than 10) or a tolerance statistic (value less than .20; Field, 2009). It
is important to note that while the EEG frequency variables were found to be highly
correlated with one another, this did not present a multicollinearity issue because each
EEG band was tested within a separate model, and thus the assumption of
multicollinearity was not violated.

CHAPTER III – RESULTS
Descriptive and Correlational Analyses of Study Variables
Means and standard deviations of relevant demographic variables and primary
variables of interest can be found in Table 2. Pearson’s bivariate correlations among the
study variables are presented in Table 3.
Table 2
Means and Standard Deviations
Variable

Range
M
SD
Min
Max
Age (in months)
87.93
144.23
121.27
16.47
FSIQ-2
92
128
108.53
9.69
SWAN T1
.74
2.81
1.62
.55
SWAN T2
-1.33
1.48
.10
.79
Alpha
.07
1.44
.49
.32
Beta1
.03
.47
.17
.10
Beta2
.02
.48
.12
.10
Theta
.14
1.25
.53
.28
Note. SWAN T1 = Caregivers’ retrospective ratings of children’s ADHD and ODD
symptom severity pre-MPH. SWAN T2 = Caregivers’ ratings of children’s ADHD and
ODD symptom severity at optimal MPH dosage. Greater SWAN scores indicate more
clinically significant symptoms.
Table 3
Bivariate Correlations among Study Variables
Variable
1
2
1. Age
—
(months)
2. FSIQ-2
.22
—
3. Alpha
.18
-.08
4. Beta1
.04
.18
5. Beta2
.13
.23
6. Theta
.06
-.02
7. SWAN T1
-.12
-.19
8. SWAN T2
.00
-.20
Note. * p < .10, **p < .05, ***p < .01

3

4

5

—
.71***
—
.56*** .87***
—
.77*** .68*** .51***
.15
.02
.04
-.35*
-.23
-.07

6

7

8

—
-.03
-.25

—
-.04

—

Test of Hypotheses
Multiple linear regressions were performed to determine the predictive ability of
EEG frequencies on SWAN scores at optimal-MPH dosage while controlling for SWAN
scores prior to MPH.
Alpha Frequency
Results of the multiple regression analysis indicated that the two predictors
explained 12.8% of the variance (F(2,27)=1.98, p <.15, R2 =.12). As can be seen in Table
4, it was found that alpha frequency was marginally statistically significantly predictive
of SWAN scores at optimal-MPH dosage while controlling for SWAN scores prior to
MPH, β = -.35, t(27) = - 1.97, p = .058. Thus, with each one-unit increase in alpha power
(i.e., alpha frequency elevation), SWAN scores at optimal-MPH dosage decreased by -.86
(i.e., improvement in symptoms) when controlling for pre-MPH SWAN scores.
Table 4
Results of Multiple Regression in Alpha Frequency Band
Variable

B

SE(B)

Constant

.51

.46

SWAN T1

.01

.25

Alpha

-.86

.43

β

t

p

1.10

.27

95% CI
LL
UL
-.44
1.46

.09

.04

.96

-.51

.54

-.35

-1.97

.06

-1.76

.03

Note. *p < 0.05.
Beta1 Frequency
Results of the multiple regression analysis indicated that the two predictors
explained 5.6% of the variance (F(2,27)=.80, p <.45, R2 =.05). As can be seen in Table 5,
it was found that beta1 frequency was not significantly predictive of SWAN scores at

optimal-MPH dosage while controlling for SWAN scores prior to MPH, β = -.03, t(27) =
- .20, p = .839.
Table 5
Results of Multiple Regression in Beta1 Frequency Band

Variable
Constant

B
.50

SE(B)
.51

β

t
.98

p
.33

95% CI
LL
UL
-.54
1.56

SWAN T1

-.05

.26

-.03

-.20

.83

-.60

.49

Beta1

-1.81

1.45

-.23

-1.24

.22

-4.80

1.17

Note. *p < 0.05.
Beta2 Frequency
Results of the multiple regression analysis indicated that the two predictors
explained 0.8% of the variance (F(2,27)=.10, p <.90, R2 =.008). As can be seen in Table
6, it was found that beta2 frequency was not significantly predictive of SWAN scores at
optimal-MPH dosage while controlling for SWAN scores prior to MPH, β = -.07, t(27) =
- .38, p = .702.
Table 6
Results of Multiple Regression in Beta2 Frequency Band

Variable
Constant

B
.27

SE(B)
.49

β
--

t
.54

p
.58

95% CI
LL
UL
-.74
1.28

SWAN T1

-.05

.27

-.04

-.21

.83

-.62

.50

Beta2

-.55

1.42

-.07

-.38

.70

-3.47

2.37

Note. *p < 0.05.

Theta Frequency
Results of the multiple regression analysis indicated that the two predictors
explained 6.9% of the variance (F(2,27)=1.10, p < .30, R2 =.069). As can be seen in Table
7, it was found that theta frequency was not significantly predictive of SWAN scores at
optimal-MPH dosage while controlling for SWAN scores prior to MPH, β = -.05, t(27) =
-1.30, p = .174.
Table 7
Results of Multiple Regression in Theta Frequency Band

Variable
Constant

B
.61

SE(B)
.53

β
--

t
1.14

p
.26

95% CI
LL
UL
-.48
1.72

SWAN T1

-.07

.26

-.05

-.29

.77

-.62

.46

Theta

-.71

.51

-.25

-1.39

.17

-1.76

.33

Note. *p < 0.05.
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CHAPTER IV – DISCUSSION
In this study, I investigated the relations between EEG frequencies and changes in
inattentive, hyperactive-impulsive, and oppositional defiant symptoms at optimal dosage
in a sample of children diagnosed with ADHD and previously trialed on MPH.
Examining these relations may lead to potential identification of biosignals that may
inform families of potential MPH response prior to initiating medication. In the sections
below, I will interpret the results of my multiple regression analyses, discuss implications
of these results, outline the limitations of this investigation, and discuss future directions
within this discussion and conclusion.
Overall, no frequency bands examined within this study met traditional statistical
significance levels (p < .05) to reject the null hypothesis, however, the alpha frequency
band approached statistical significance, which warrants further examination in future
studies. Hypothesis 1 postulated that reduced alpha frequency would predict greater
symptom improvement (i.e., a significant negative relation between variables of interest)
based on previous literature suggesting youth with ADHD demonstrate decreased
absolute alpha frequency compared to typically-developing peers (Kirkland & Holton,
2019, Lenartowicz & Loo, 2014). The alpha frequency multiple regression result from
this investigation appears to be in concordance with several previous investigations
which have demonstrated reduced baseline alpha (Barry et al., 2009; Clarke et al., 2002;
Clarke et al., 2003; Clarke et al, 20008) among ADHD populations. These results and the
extant literature are also congruent with neurophysiological literature suggesting that
resting alpha power reflects attentional processes such as alertness and hypervigilance
(Klimesch, 1999) as well as creative ideation (Schwab et al., 2014).
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Surprisingly, Beta1, Beta2, and Theta frequencies were not predictive of
retrospective perceived change in ADHD and ODD symptoms at optimal MPH dosage.
These results are counter to Loo and colleagues’ (2004) results, which found a significant
positive relation between frontal beta and ADHD symptom improvement, as well as a
significant negative relation between frontal theta and improvements in inattention
symptoms. However, there are several caveats to consider in making this comparison,
namely, that Loo and colleagues’ (2004) investigation examined both baseline
neurophysiology and re-tested while on stimulant medication. The results of the current
investigation are also counter to Gokten and colleagues (2019), who found that decreased
beta and increased frontal delta, frontal theta, and central theta were related to caregiverreported symptom improvement on MPH.
From a neurophysiological perspective, an important caveat is that each frequency
band was averaged across regions for the purposes of the current study as a practical
constraint. Given marginally significant results within the alpha frequency band, it is
possible that specification of region-specific variables may yield statistically significant
findings and allow for further comparisons with other investigations. Further, given that
only baseline neurophysiology was measured, it is likely that a re-test of the EEG
paradigm with MPH administration would further illuminate these relations and allow for
direct comparisons. However, methodological differences are likely to exist within
medication administration procedures, complicating direct comparisons. The numerous
inconsistent findings within the EEG literature investigating ADHD populations are
thought to reflect methodological differences, such as eyes-open versus eyes-closed
paradigms or cognitive activation tasks (Loo et al., 2004).
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The current study has several notable strengths. First, this investigation examined
change in both ADHD and ODD symptoms utilizing a dimensional, continuum measure
which captures both adaptive and maladaptive presentations. The use of the SWAN
serves as an attempt to more accurately examine an individual’s behavioral presentation
in the context of their culture-specific and age-related norms, rather than categorical
ratings of psychopathology, as intended by the authors (Brites et al., 2015, Swanson et
al., 2009). The SWAN been used in investigations across cultures; tests of statistical
stability by translation and validation for other languages has yielded promising results,
overall reports suggest excellent specificity, excellent stability, and good internal
consistency among translated versions of the scale (Brites et al., 2015).
Second, this investigation examined a population of children in middle childhood
(ages 7-12) years, reflective of the average range in which most children diagnosed with
ADHD initiate a stimulant medication trial (Swanson & Volkow, 2009). Third, this study
utilized a residualized change score model based on theoretical reasoning and
recommendations from Castro-Schilo and Grimm (2018) to reduce statistical bias for
two-occurrence continuous data. I am aware of several investigations that have examined
ADHD change score outcomes, however, most have examined this change by calculation
of difference scores, which are noted to be highly prone to statistical bias (Castro-Schilo
& Grimm, 2018).
Despite these outlined strengths, there were several limitations of the current
study. The small sample size of this investigation impacted statistical power and thus was
more susceptible to Type II error, or the failure to reject the null hypotheses. It is possible
that low statistical power may be responsible for null results, given that a sample size of
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68 was recommended. Additionally, although sample demographics were reflective of the
region, participants in this investigation were predominantly European American,
limiting generalizability. Future research should examine correlates of MPH response
among participants and caregivers from diverse racial, ethnic, socioeconomic, and gender
identity backgrounds. Perhaps the most important caveat of this investigation, this study
employed retrospective caregiver ratings, which should be interpreted with caution due to
the high potential for caregiver recall bias (Miller et al., 2009).
It is also important to note that a majority of the data for this investigation was
collected during the height of the COVID-19 pandemic. While research methods were
not altered for the purposes of this investigation, it is possible that this may have
influenced the selection of caregivers who enrolled in the study as well as caregiver’s
retrospective ratings of their child’s ADHD and ODD symptoms. Results from a recent
investigation of the impact of the COVID-19 pandemic on caregivers of those with
developmental disabilities such as ADHD found that COVID-19 related difficulties with
childcare resources significantly predicted higher caregiver burden scores on the Burden
Scale for Family Caregivers (Iovino et al., 2021). There exists the possibility that those
with greater caregiver burden were not included in this study due to caregiver-related
time constraints. Crucially, this study did not examine caregivers’ symptoms of ADHD.
It is possible that inattentive and/or hyperactive-impulsive symptoms among caregivers
could have influenced their ratings of their child’s ADHD and ODD symptoms. A 2009
investigation by Miller, Newcorn, and Halperin examining retrospective recall
inaccuracies among parents of adolescent youth diagnosed with ADHD further supports
this possibility. The authors found that current symptom severity in late adolescence and
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early adulthood influenced both youth and parents recall of childhood symptoms (Miller
et al., 2009). Future research examining MPH response would likely benefit from
additional raters within other settings, such as participants’ teachers, utilizing a
prospective design with multiple informants.
Additionally, while the investigation examined baseline neurophysiological
predictors that may predict MPH response, children did not undergo a re-test of the
resting state EEG paradigm while on their optimal MPH dosage. Although all children
refrained from prescribed ADHD medications during a 48-hour medication washout,
some literature suggests that prior use of stimulants may alter baseline
neurophysiological functioning (Pertermann et al., 2019; Robertson et al., 2019).
Relatedly, this study employed a cross-sectional design, thus, no causation can be
inferred from study findings.
Conclusions
The study’s primary goal was to examine associations of EEG frequency bands
and caregiver perceived change in children’s ADHD and ODD symptoms at optimal
MPH dosage. Although no frequency bands reached traditional statistical significance
levels, results suggest the alpha band frequency should be examined in future
investigations of behavioral changes following stimulant medication. These findings
provide novelty to the extant literature examining neurophysiological indices of MPH
response with the inclusion of ODD symptoms. A trial-and-error approach to stimulant
medications have the potential to cause worry and distress within families and can
potentially lead to early discontinuation of effective treatment (Toomey et al., 2012)
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These preliminary results should be further explored to identify neurophysiological
stimulant response phenotypes among children with ADHD.
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